The Clinical Efficacy of Capecitabine Metronomic Chemotherapy in the Treatment of Elderly Patients with Advanced Gastric Cancer

沈婕,何胜利,孙贤俊,朱晓娟,高勇

DOI: https://doi.org/10.3781/j.issn.1000-7431.2010.09.014

2010-01-01

Tumori

Abstract:Objective:To evaluate the clinical efficacy and adverse reaction of continuous low dose capecitabine metronomic chemotherapy for the elderly patients with advanced gastric cancer.Methods:Twenty-eight elderly patients with advanced gastric cancer were given continuous low dose capecitabine.Capecitabine was administered orally at a dose of 500 mg twice a day for 28 days followed by a 7-day rest period.The therapeutic regimen was repeated every 4 weeks.Totally 2 to 13 cycles were completed.The median number of chemotherapy cycles was four.The efficacy was evaluated in patients who received at least 2 cycles of chemotherapy.Results:Of the 28 patients,no patient achieved complete remission,4 patients achieved partial remission(14.3%) after 3 cycles of chemotherapy,7 patients maintained a stable disease(25%).The disease control rate was 39.3%(11/28).The median time to progression(TTP) was 3.1 months(4.5-6.2 months) and the median overall survival(OS) was 7.2 months(4.9-9.4 months).The major toxicity included leukopenia,thrombocytopenia and hand-foot syndrome at grade I or II.Conclusion:The metronomic chemotherapy regimen with continuous low dose capecitabine is effective in controlling the progression of decrease for elderly patients with advanced gastric cancer.The adverse reaction was mild.It deserves further clinical observation.